financetom
Business
financetom
/
Business
/
Core & Main Completes Acquisition of ACF West
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Core & Main Completes Acquisition of ACF West
Apr 1, 2024 3:05 PM

05:34 PM EDT, 04/01/2024 (MT Newswires) -- Core & Main ( CNM ) said Monday it completed the previously announced acquisition of NW Geosynthetics, doing business as ACF West.

Financial details weren't disclosed.

ACF West is a supplier of geosynthetic materials and offers soil stabilization services through six branches in Oregon, Washington, Idaho and Utah, the company said.

Price: 57.26, Change: -0.02, Percent Change: -0.03

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
--India's Regulator Approves Disney-Reliance Media Merger
--India's Regulator Approves Disney-Reliance Media Merger
Aug 29, 2024
07:32 AM EDT, 08/28/2024 (MT Newswires) -- Price: 90.93, Change: +0.03, Percent Change: +0.03 ...
Grown Rogue Subsidiary Begins Operations in New Jersey
Grown Rogue Subsidiary Begins Operations in New Jersey
Aug 29, 2024
08:05 AM EDT, 08/28/2024 (MT Newswires) -- Grown Rogue International ( GRUSF ) , a craft cannabis company, on Wednesday said subsidiary ABCO Garden State, a licensed cannabis cultivator in New Jersey, began Phase I operations. Phase I includes about 8,000 sq ft of flowering canopy, as measured by bench space, that should produce 500 to 600 pounds of craft...
Elevai Labs, Yuva Biosciences File 2 Hair Treatment Patents
Elevai Labs, Yuva Biosciences File 2 Hair Treatment Patents
Aug 29, 2024
08:03 AM EDT, 08/28/2024 (MT Newswires) -- Elevai Labs ( ELAB ) said Wednesday it has filed two hair and scalp vitality patents in collaboration with Yuva Biosciences. The first patent is for a skin, scalp, and hair improvement treatment while the second patent covers the use of exosomes as a delivery system, the company said. Price: 0.3101, Change: -0.01,...
Neurocrine Biosciences' Schizophrenia Drug Shows 'Significant' Symptom Reduction in Phase 2 Trial
Neurocrine Biosciences' Schizophrenia Drug Shows 'Significant' Symptom Reduction in Phase 2 Trial
Aug 29, 2024
08:07 AM EDT, 08/28/2024 (MT Newswires) -- Neurocrine Biosciences ( NBIX ) said Wednesday a phase 2 dose-finding study of its investigational drug NBI-1117568 in adult patients with schizophrenia showed 'statistically significant' reduction in symptom severity. The tests also demonstrated 'statistically significant improvement' in additional scales for schizophrenia symptoms, Neurocrine said. The test's goal was to determine a once-daily well-tolerated...
Copyright 2023-2026 - www.financetom.com All Rights Reserved